SCHEMBL5227352

SCHEMBL5227352

CCOC(=O)CN(Cc1ccc(O)cc1)S(=O)(=O)NC(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA7 P43166 2/20 0.48
CA14 Q9ULX7 2/20 0.48
ALDH1A1 P00352 1/20 0.40
AKT1 P31749 3/20 0.40
KMT2A Q03164 1/20 0.40
CTSS P25774 3/20 0.39
CTSL P07711 2/20 0.39
CTSB P07858 2/20 0.39
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.38
MIF P14174 1/20 0.38
PTPRB P23467 1/20 0.37
POLB P06746 1/20 0.36
CTSK P43235 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5443979 0.87 BCL2 (0.48) CA12CA1CA7CA14ALDH1A1
SCHEMBL5229900 0.76 KMT2A (0.47) CA12CA1CA7CA14ALDH1A1
SCHEMBL5428031 0.75 PPARG (0.59)
SCHEMBL14375790 0.74 POLB (0.50) CA12CA1ALDH1A1KMT2APOLB
SCHEMBL6818212 0.72 PPID (0.41) CA12CA1CA7CA14ALDH1A1
SCHEMBL5225261 0.72 LTA4H (0.47) ALDH1A1
SCHEMBL4291282 0.72 CTSS (0.51) CTSSCTSLCTSBCTSK
SCHEMBL4976482 0.72 CTSS (0.51) CTSSCTSLCTSBCTSK
SCHEMBL4976485 0.72 CTSS (0.51) CTSSCTSLCTSBCTSK
SCHEMBL16706555 0.71 ALDH1A1 (0.40) ALDH1A1KMT2APOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007136570-A2 5,6-FUSED PYRROLIDINE COMPOUNDS USEFUL AS TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-11-29 WO disclosed
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 CA12 2797/4885CA1 3138/4885CA7 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.